The FDA Gift That Keeps On Giving: Johnson & Johnson (JNJ), Bristol Myers Squibb Co. (BMY)

Eight months ago, Bayer and Johnson & Johnson (NYSE:JNJ) announced that the Food and Drug Administration had issued a complete response letter for their anticoagulant, Xarelto. This week, the duo got another one. And back in 2009, the companies got a complete response letter for Xarelto for a different indication.

This isn’t one of those gifts that are fun to receive once, let alone multiple times. While it goes by an ambiguous name, a “complete response letter” is essentially a rejection letter. It’s issued when the review is complete, but there are issues keeping the drug from being approved.

Johnson & Johnson (NYSE:JNJ)The FDA rejection last year came as a result of missing data from the clinical trial that Bayer and Johnson & Johnson were using to expand the use of Xarelto to treat patients with acute coronary syndrome. A whopping 63% of the patients had not followed through with the trial.

The companies tracked down most of the patients to figure out whether they were still alive, and submitted follow up data showing that deaths of the missing patients were equally distributed between the three treatment groups — two drug dosages and one placebo — suggesting that the mortality benefit was maintained.

Bayer and Johnson & Johnson (NYSE:JNJ) didn’t go into specifics as to what current concerns the FDA has with approving Xarelto for acute coronary syndrome. It could still be with the missing data, but my best guess is that the agency is worried about the increase in bleeding seen in patients taking Xarelto. The bleeding didn’t kill more patients, but it’s still a complication that has to be taken seriously. Eli Lilly & Co. (NYSE:LLY)‘s Effient and AstraZeneca plc (ADR) (NYSE:AZN)‘s Brilinta have the same bleeding issue in acute coronary syndrome patients, but the drugs were able to get approved by the FDA.

Xarelto is in the same class of drugs — Factor X inhibitors — as Bristol Myers Squibb Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFE)‘s Eliquis and Boehringer Ingelheim’s Pradaxa. The drugs can be used to treat a variety of cardiovascular issues, such as preventing and treating blood clots, and in patients with an irregular heart beat called atrial fibrillation. Xarelto is approved for those indications, but Eliquis has superior data for atrial fibrillation and is likely to capture most of those patients. Acute coronary syndrome was supposed to be where Xarelto could fit in, because it’s the only Factor X inhibitor that’s shown a reduction in heart attacks.

Unless the FDA turns its gift of coal into a real gift, those sales don’t look like they’ll be forthcoming.

The article The FDA Gift That Keeps On Giving originally appeared on Fool.com.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!